טוען...
HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients
BACKGROUND: Despite a typically good response to first-line combination chemotherapy, the prognosis for patients with advanced ovarian cancer remains poor because of acquired chemoresistance. The use of targeted therapies such as trastuzumab may potentially improve outcomes for patients with ovarian...
שמור ב:
| Main Authors: | , , , , , , , , , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Public Library of Science
2007
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2042515/ https://ncbi.nlm.nih.gov/pubmed/17987122 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0001138 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|